Our Commitment to Corporate Ethics

Basic approach

Our basic philosophy is that corporate ethics take priority over profit, a message that we continue to communicate to all employees.

With the launch of the new Chugai in October of 2002, management issued a new basic philosophy that corporate ethics take priority over profit, a message that continues to be communicated today and that is shared among all employees. In working to achieve its Mission Statement, exemplifying a company that fulfills its responsibilities to society and responds to the expectations of its stakeholders, Chugai has established the Chugai Business Conduct Guidelines (Chugai BCG), and regularly reviews and revises its content in accordance with societal changes.

Chugai places paramount importance on respect for life and strives for fair and transparent corporate activities based on high ethical standards, along with sincere scientific initiatives. Specifically, through corporate ethics training and other programs, all Chugai employees share the Core Values of the Company. They understand the ethical standards necessary to execute the business of a healthcare company and follow those standards every day, based on the guidance of the Chugai BCG.

Commitment to Ethical Corporate Activities

We have established our own Chugai Code of Practice and promote a high standard of ethical corporate behavior.

The foreword to the IFPMA Code of Practice begins, “Advancing medical knowledge and improving global public health depend on information-sharing interactions by the entire medical community—from researcher to attending physician and nurse to patient—and integrity is essential to these exchanges. Fundamentally, there must always be confidence that prescription decisions are made on an ethical and patient-focused basis.”

The Chugai Group is a proactive participant in the Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry, the entity which administers the pharmaceutical industry’s voluntary guidelines, and in the Code Committee of the Japan Pharmaceutical Manufacturers Association. We have also established our own Chugai Code of Practice, and we promote ethical corporate behavior not only in our promotional activities, but also in the interactions between all of our officers and employees with researchers, medical professionals and patient groups.

Creating a Corporate Culture of Respect for Self and Others

The keyword can be translated into English as, “You can respect others if you can respect yourself.”

We work to establish workplaces where co-workers value each other based on an organizational climate of respect for self and others.

Among the guidelines for conduct included in the Chugai BCG are items that emphasize the importance of respect for human rights and promotion of diversity. Chugai’s corporate culture is based on respect for self and others. It is a culture in which individual employees have strong self-esteem, and in which, as diverse individuals interact with one another, they recognize each other’s values and promote respect for diversity—in short, we work to create workplaces that are free from harassment and infringement of human rights, and where co-workers value each other.

A corporate culture that respects human rights allows diverse individuals to make the most of their capabilities, thus improving performance. Moreover, by raising awareness of human rights and by promoting respect for diversity within Chugai, such a culture helps eliminate discrimination and infringement of human rights in the broader society as Chugai interacts with the public and through the everyday lives of its people.

Creating Workplaces Free from Harassment

In addition to establishing a harassment hotline, we have assigned area counselors at each branch, plant, and research laboratory, giving employees someone familiar with whom they can consult.

The Chugai Group strives to foster respect for diverse personalities and values, to create workplaces where both male and female employees can work with enthusiasm and peace of mind. Accordingly, to prevent sexual harassment and power harassment (abuse of power) in the workplace, we take various measures to educate employees and raise their awareness about these issues, including distributing a sexual harassment prevention handbook to every employee, and working from a handbook on creating workplaces free from power harassment in training for managers. Additionally, under amendments to the law that took effect on January 1, 2017, business owners are now required to have in place measures to prevent harassment of employees who are pregnant or have given birth, or who take child or family care leave. Based on those changes, the Chugai Group has revised its employment regulations and harassment prevention rules, which now prohibit unfavorable treatment of employees for use of our programs for maternity, have given birth, child care and family care leave, as well as behavior that creates a hostile work environment for such employees.

We have established a harassment hotline in the Corporate Social Responsibility Department, enabling employees to discuss their concerns freely, and have assigned area counselors at each branch, plant, and research laboratory, giving employees someone familiar with whom they can consult. Harassment consultation training by outside instructors and harassment hotline personnel is provided regularly for these area counselors and human resource managers to reinforce the knowledge and skills necessary to respond to calls.

We have established a definition of power harassment and are conducting workshops for managers in each department.

In October 2012, we established a definition of power harassment at the Chugai Group, as well as basic policies and regulations to prevent it. Since then, we have been conducting power harassment prevention workshops for managers in each department. This is one of the practical measures we take to foster harassment-free workplaces where people can work with enthusiasm.

Conduct of Clinical Trials

Clinical trials are strictly conducted in accordance with global standards, respecting the rights of trial subjects and closely monitoring for patient safety based on high ethical standards.

Clinical trials are essential for verifying the safety and efficacy of investigational products, and they must be performed with respect for the rights of trial subjects. At Chugai, clinical trials are closely monitored for patient safety, following stringent scientific methodology based on the highest ethical standards and scientific standards.

The Chugai Group has created standardized procedural manuals based on Japan’s Pharmaceutical and Medical Devices Act and other related legislation, as well as on the current revision of the Declaration of Helsinki*1 and ICH-GCP*2, which are global standards. We are committed to evaluating the true value of investigational products using well-established, reputable testing procedures.

Plans for clinical trials are first drafted by experts in fields such as medicine, statistics, and safety. The actual trials are implemented based on a written plan that has been fully reviewed both internally and by outside medical institutions to ensure that it is ethically and scientifically sound. Once a trial has begun, information on safety is promptly collected and analyzed, and when necessary, that information is shared with regulatory authorities and the medical institutions involved, ensuring that patient welfare always remains the highest priority. The quality of clinical trials is also carefully managed, with a variety of steps in place to ensure the reliability of trial results.

  • *1.The “Ethical Principles for Medical Research Involving Human Subjects” first adopted at the World Medical Association in 1964. Biomedical research must ultimately include testing on human subjects in order to contribute to healthcare. The 1964 Declaration of Helsinki is the ethical foundation of modern clinical trials. (Source: The Pharmaceutical Society of Japan)
  • *2.Good Clinical Practice (GCP) guidelines adopted by the International Conference on Harmonisation (ICH) for conducting pharmaceutical clinical trials in the European Union, the United States and Japan.
    (Source: The Pharmaceuticals and Medical Devices Agency)
  • Like
  • Tweet
  • LINE it!
  • E-mail

Chugai's Approach to CSR

Back to top